A Phase 3 interventional study of VX-661 Plus Ivacaftor Combination and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 75 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-06-12.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 2nd largest by enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 4th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2015.
This study's enrollment of 510 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 7th largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 37th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double blind, placebo controlled, parallel group, multicenter study in people with cystic fibrosis (CF) who are homozygous for the F508del CF transmembrane conductance regulator (CFTR) gene mutation.
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in people with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the efficacy and safety of VX-661 in combination with Ivacaftor (IVA, VX-770). The active treatment regimen comprised of a morning dose of a fixed-dose combination (FDC) tablet of 100 milligram (mg) VX-661/150 mg IVA once daily (qd) and an evening dose of IVA 150 mg to be taken approximately 12 hours after the morning dose. The placebo regimen was visually matched tablets to be taken with the same schedule as the active treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
Drug: VX-661 Plus Ivacaftor Combination Placebo · Drug: Ivacaftor placebo
VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
Drug: VX-661 Plus Ivacaftor Combination · Drug: Ivacaftor
Drug pages: Tezacaftor · Ivacaftor
FDC tablet, oral use
Tablet, oral use
FDC tablet, oral use
Tablet, oral use
Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Day 1, Through Week 24
Relative Change From Baseline (Day 1) in ppFEV1 Through Week 24
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Day 1, Through Week 24
Number of Pulmonary Exacerbations Per Year
Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Pulmonary exacerbation events per year (48 weeks) were reported.
Time frame: Day 1 through Week 24
Absolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 24
BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).
Time frame: Day 1, Week 24
Absolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Day 1, Through Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.
Time frame: Day 1 up to Week 28
Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24
Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Time to event data was not collected and instead, Number of Subjects with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
Time frame: Day 1 through Week 24
Absolute Change From Baseline (Day 1) in Sweat Chloride Through Week 24
Sweat samples were collected using an approved collection device.
Time frame: Day 1, Through Week 24
Absolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening)
BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).
Time frame: Day 1, Week 24
Absolute Change From Baseline (Day 1) in Body Weight at Week 24
Time frame: Day 1, Week 24
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolites (M1 VX-661 and M2-VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
This outcome was not planned to be assessed in Placebo arm.
Time frame: Pre-morning dose on Week 16
The study was conducted across 91 sites in 12 countries.
| Milestone | Placebo | VX-661/IVA |
|---|---|---|
| Started | 259 | 251 |
| Treated | 258 | 251 |
| Completed | 241 | 236 |
| Not completed | 18 | 15 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Other | 3 | 3 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Percentage of predicted FEV1 | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline (Day 1) in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 24 | -0.6 (-1.3 to 0.0) | 3.4 (2.7 to 4.0) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Placebo | VX-661/IVA |
|---|---|---|
| Relative Change From Baseline (Day 1) in ppFEV1 Through Week 24 | -0.5 (-1.7 to 0.6) | 6.3 (5.1 to 7.4) |
Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Pulmonary exacerbation events per year (48 weeks) were reported.
| pulmonary exacerbation events per year | Placebo | VX-661/IVA |
|---|---|---|
| Number of Pulmonary Exacerbations Per Year | 0.99 | 0.64 |
BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).
| kilogram per square meter (kg/m^2) | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline (Day 1) Body Mass Index (BMI) at Week 24 | 0.12 (0.03 to 0.22) | 0.18 (0.08 to 0.28) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline (Day 1) in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 24 | -0.1 (-1.6 to 1.4) | 5.0 (3.5 to 6.5) |
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 28 was considered treatment-emergent.
| Participants | Placebo | VX-661/IVA |
|---|---|---|
| Participants with AEs | 245 | 227 |
| Participants with SAEs | 47 | 31 |
Pulmonary exacerbation was defined as a new event or change in antibiotic therapy for greater than or equal to 4 sinopulmonary signs/symptoms. Time to event data was not collected and instead, Number of Subjects with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
| Participants | Placebo | VX-661/IVA |
|---|---|---|
| Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24 | 88 | 62 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline (Day 1) in Sweat Chloride Through Week 24 | 0.2 (-0.8 to 1.2) | -9.9 (-10.9 to -8.9) |
BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).
| z-score | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline (Day 1) in BMI Z-score at Week 24 in Participants Less Than (<) 20 Years Old at the Time of Screening) | -0.02 (-0.10 to 0.06) | -0.06 (-0.14 to 0.02) |
| kg | Placebo | VX-661/IVA |
|---|---|---|
| Absolute Change From Baseline (Day 1) in Body Weight at Week 24 | 0.6 (0.3 to 0.9) | 0.7 (0.4 to 1.0) |
This outcome was not planned to be assessed in Placebo arm.
| nanogram per milliliter (ng/mL) | VX-661/IVA |
|---|---|
| VX-661 | 1890 ± 1150 |
| M1 VX-661 | 4730 ± 1730 |
| M2 VX-661 | 4830 ± 2750 |
| IVA | 815 ± 572 |
| M1 IVA | 1590 ± 961 |
Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/258 (0%) | 47/258 (18.2%) | 243/258 (94.2%) |
| VX-661/IVA | 0/251 (0%) | 31/251 (12.4%) | 227/251 (90.4%) |
| Event | Placebo | VX-661/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 32/258 | 23/251 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 3/258 | 3/251 |
| PneumoniaInfections and infestations | 1/258 | 2/251 |
| ConstipationGastrointestinal disorders | 2/258 | 0/251 |
| Acute kidney injuryRenal and urinary disorders | 2/258 | 0/251 |
| Clostridium difficile colitisInfections and infestations | 0/258 | 1/251 |
| Lung abscessInfections and infestations | 0/258 | 1/251 |
| Respiratory tract infection viralInfections and infestations | 0/258 | 1/251 |
| Benign intracranial hypertensionNervous system disorders | 0/258 | 1/251 |
| Generalised tonic-clonic seizureNervous system disorders | 0/258 | 1/251 |
| Event | Placebo | VX-661/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 83/258 | 66/251 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 75/258 | 57/251 |
| HeadacheNervous system disorders | 36/258 | 44/251 |
| NasopharyngitisInfections and infestations | 39/258 | 42/251 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 42/258 | 36/251 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 33/258 | 24/251 |
| PyrexiaGeneral disorders | 32/258 | 28/251 |
| FatigueGeneral disorders | 30/258 | 16/251 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 29/258 | 22/251 |
| Abdominal painGastrointestinal disorders | 22/258 | 23/251 |
Full Analysis Set (FAS) included all randomized participants who carried the intended cystic fibrosis transmembrane conductance regulator (CFTR) allele mutation and had received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | VX-661/IVA | Total |
|---|---|---|---|
| Mean | 25.7 ± 9.5 | 26.9 ± 11.2 | 26.3 ± 10.4 |
| Sex: Female, Male(Participants) | Placebo | VX-661/IVA | Total |
|---|---|---|---|
| Female | 125 | 121 | 246 |
| Male | 131 | 127 | 258 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | VX-661/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 9 | 12 |
| Not Hispanic or Latino | 250 | 234 | 484 |
| Unknown or Not Reported | 3 | 5 | 8 |
| Race (NIH/OMB)(Participants) | Placebo | VX-661/IVA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 254 | 245 | 499 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Jan 2017, 24 months.
Results were first posted in Jun 2018, 1 year 4 months after primary completion. A results delay was requested in Feb 2018.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 24 months is close to that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →